organization · Reporting owner
Dexxon Holdings Ltd.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Roivant Sciences Ltd.ROIV · Entity 3185 | 10% owner | November 10, 2022 | November 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Roivant Sciences Ltd.
Report date November 10, 2022 · Filed November 14, 2022
Jointly reported with Dexcel Pharma Technologies Ltd., Oren Dan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 102,849,443 |
Reported balance
After 2022-11-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-11-10 · Purchase · Acquired 4,000,000 · Balance 102,849,443 F1: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. F2: The common shares were purchased by Dexcel in a registered public offering on November 10, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
F2: The common shares were purchased by Dexcel in a registered public offering on November 10, 2022.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arbutus Biopharma Corp
Report date July 10, 2019 · Filed July 12, 2019
Jointly reported with Dexcel Pharma Technologies Ltd., Oren Dan
Section 16 reporting ended · disclosed 2019-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Myovant Sciences Ltd.
Report date July 10, 2019 · Filed July 12, 2019
Jointly reported with Dexcel Pharma Technologies Ltd., Oren Dan
Section 16 reporting ended · disclosed 2019-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Sio Gene Therapies Inc.
Report date July 10, 2019 · Filed July 12, 2019
Jointly reported with Dexcel Pharma Technologies Ltd., Oren Dan
Section 16 reporting ended · disclosed 2019-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Urovant Sciences Ltd.
Report date July 10, 2019 · Filed July 12, 2019
Jointly reported with Dexcel Pharma Technologies Ltd., Oren Dan
Section 16 reporting ended · disclosed 2019-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2022 Filed Nov 14, 2022 13:40 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | PurchaseCommon Shares | 4,000,000 | $5.00 | $20,000,000.00 |
DisclosureSEC source: 0001104659-22-117847 · tm2230168d1_4.xml · nonDerivative · entry 1 Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,849,443 F1 · shares: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. F2 · price: The common shares were purchased by Dexcel in a registered public offering on November 10, 2022. Read SEC document |
| April 25, 2022 Filed Apr 26, 2022 10:48 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | PurchaseCommon Shares | 8,600 | $3.91 | $33,635.46 |
DisclosureSEC source: 0001104659-22-049930 · tm2213532d1_4.xml · nonDerivative · entry 2 Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,849,443 F1 · shares: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. F3 · price: The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99. F4 · price: The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · acquired: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. Read SEC document |
| April 22, 2022 Filed Apr 26, 2022 10:48 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | PurchaseCommon Shares | 31,685 | $3.83 | $121,318.70 |
DisclosureSEC source: 0001104659-22-049930 · tm2213532d1_4.xml · nonDerivative · entry 1 Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,840,843 F1 · shares: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. F2 · price: The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88. F4 · price: The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · acquired: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity. Read SEC document |
| June 19, 2019 Filed Jun 19, 2019 18:24 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 4,957 | $8.17 | $40,495.22 |
DisclosureSEC source: 0001144204-19-031542 · tv523822_4.xml · nonDerivative · entry 3 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,860,013 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F6 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 18:24 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 6,706 | $8.21 | $55,060.95 |
DisclosureSEC source: 0001144204-19-031542 · tv523822_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,855,056 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 18:24 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 6,541 | $8.53 | $55,824.82 |
DisclosureSEC source: 0001144204-19-031542 · tv523822_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,848,350 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 18:10 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 7,144 | $7.91 | $56,514.04 |
DisclosureSEC source: 0001144204-19-031054 · tv523638_4.xml · nonDerivative · entry 3 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,841,809 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F6 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $8.00, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 18:10 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 7,367 | $7.95 | $58,542.60 |
DisclosureSEC source: 0001144204-19-031054 · tv523638_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,834,665 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.67 to $8.39, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:10 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 7,500 | $8.30 | $62,244.00 |
DisclosureSEC source: 0001144204-19-031054 · tv523638_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,827,298 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.16 to $8.77, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 18:19 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 7,189 | $8.58 | $61,693.84 |
DisclosureSEC source: 0001144204-19-030612 · tv523411_4.xml · nonDerivative · entry 3 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,819,798 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F6 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.41 to $8.75, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 18:19 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 7,500 | $8.35 | $62,594.25 |
DisclosureSEC source: 0001144204-19-030612 · tv523411_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,812,609 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.89 to $8.68, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 18:19 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 6,649 | $7.97 | $52,959.29 |
DisclosureSEC source: 0001144204-19-030612 · tv523411_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,805,109 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.10, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 06, 2019 Filed Jun 6, 2019 18:25 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 7,082 | $8.00 | $56,621.30 |
DisclosureSEC source: 0001144204-19-030138 · tv523225_4.xml · nonDerivative · entry 3 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,798,460 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F6 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 18:25 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 6,540 | $8.02 | $52,418.10 |
DisclosureSEC source: 0001144204-19-030138 · tv523225_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,791,378 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares, $0.000017727 par value per share | 2,424,242 | $8.25 | $19,999,996.50 |
DisclosureSEC source: 0001144204-19-030140 · tv523092_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 40,765,599 F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Myovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:25 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 7,500 | $7.59 | $56,910.75 |
DisclosureSEC source: 0001144204-19-030138 · tv523225_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,784,838 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 18:33 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 5,424 | $7.71 | $41,814.70 |
DisclosureSEC source: 0001144204-19-029540 · tv522951_4.xml · nonDerivative · entry 4 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,777,338 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F7 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.64 to $7.74, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 18:33 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 5,071 | $7.70 | $39,042.14 |
DisclosureSEC source: 0001144204-19-029540 · tv522951_4.xml · nonDerivative · entry 3 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,771,914 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F6 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.41 to $7.84, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:33 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 300 | $8.91 | $2,671.98 |
DisclosureSEC source: 0001144204-19-029540 · tv522951_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,766,843 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.71 to $9.03, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:33 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 6,951 | $7.97 | $55,417.54 |
DisclosureSEC source: 0001144204-19-029540 · tv522951_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,766,543 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.70 to $8.70, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 29, 2019 Filed May 29, 2019 18:28 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 6,882 | $7.55 | $51,983.19 |
DisclosureSEC source: 0001144204-19-028688 · tv522616_4.xml · nonDerivative · entry 3 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,759,592 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F6 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 28, 2019 Filed May 29, 2019 18:28 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 3,807 | $7.68 | $29,244.61 |
DisclosureSEC source: 0001144204-19-028688 · tv522616_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,752,710 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 24, 2019 Filed May 29, 2019 18:28 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 3,796 | $7.70 | $29,233.38 |
DisclosureSEC source: 0001144204-19-028688 · tv522616_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,748,903 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 23, 2019 Filed May 28, 2019 16:41 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 4,802 | $7.76 | $37,252.00 |
DisclosureSEC source: 0001144204-19-028456 · tv522522_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,745,107 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F6 · shares: The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 22, 2019 Filed May 28, 2019 16:41 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 5,033 | $8.06 | $40,557.93 |
DisclosureSEC source: 0001144204-19-028456 · tv522522_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,740,305 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 21, 2019 Filed May 23, 2019 17:04 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 9,995 | $8.52 | $85,108.42 |
DisclosureSEC source: 0001144204-19-027995 · tv522327_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,735,272 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 20, 2019 Filed May 22, 2019 16:21 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 1,715 | $8.39 | $14,383.19 |
DisclosureSEC source: 0001144204-19-027731 · tv522008_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,725,277 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.36 to $8.47, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 20, 2019 Filed May 22, 2019 16:21 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 8,285 | $7.98 | $66,141.64 |
DisclosureSEC source: 0001144204-19-027731 · tv522008_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,723,562 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.35 to $8.35, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 17, 2019 Filed May 20, 2019 16:21 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares | 6,200 | $7.36 | $45,641.30 |
DisclosureSEC source: 0001144204-19-027306 · tv522005_4.xml · nonDerivative · entry 2 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,715,277 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.03 - $7.85, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| May 16, 2019 Filed May 20, 2019 16:21 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 5,408 | $6.79 | $36,718.16 |
DisclosureSEC source: 0001144204-19-027306 · tv522005_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,709,077 F3 · shares: Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $6.70 to $6.93, inclusive. F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 17:04 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | PurchaseCommon Shares, $0.00001 par value per share | 6,666,667 | $1.50 | $10,000,000.50 |
DisclosureSEC source: 0001144204-19-014887 · tv516472_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 105,952,381 F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 07:29 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | PurchaseCommon Shares, $0.00001 par value per share | 10,000,000 | $1.00 | $10,000,000.00 |
DisclosureSEC source: 0001144204-18-065508 · tv509477_form4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 99,285,714 F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:58 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, $0.000037453 par value per share | 2,678,571 | $14.00 | $37,499,994.00 |
DisclosureSEC source: 0001144204-18-052388 · tv504072_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,703,669 F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 08:43 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | PurchaseCommon Shares, $0.00001 par value per share | 14,285,714 | $1.75 | $24,999,999.50 |
DisclosureSEC source: 0001144204-18-033168 · tv495927_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 89,285,714 F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 19:18 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares, $0.000017727 par value per share | 1,110,015 | $20.27 | $22,500,004.05 |
DisclosureSEC source: 0001144204-18-019287 · tv490385_4.xml · nonDerivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 38,341,357 F1 · ownership.nature: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Myovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares. F2 · ownership.nature: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 13:56 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | PurchaseSeries A Participating Convertible Preferred Shares · Derivative | 664,000 | $100.00 Strike: $7.13 | $66,400,000.00 |
DisclosureSEC source: 0001144204-18-002187 · tv476968_4.xml · derivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes 3 and 4 Disclosed balance after: 1,164,000 Underlying: Common shares, no par value · 13,025,536 shares Expires 2021-10-16 F1 · security: Represents series A participating convertible preferred shares (the "Preferred Shares") purchased by Roivant Sciences Ltd. ("Roivant") for $100.00 per Preferred Share (the "Purchase Price"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. F2 · derivative.exercise_price: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · shares: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · price: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · derivative.exercise_date: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · derivative.expiration_date: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · derivative.underlying_shares: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F3 · ownership.direct: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the Preferred Shares held by Roivant. Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Preferred Shares. F4 · ownership.direct: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Preferred Shares owned directly by Roivant. The Reporting Persons do not directly own any Preferred Shares. The Reporting Persons disclaim beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 16:48 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | PurchaseSeries A Participating Convertible Preferred Shares · Derivative | 500,000 | $100.00 Strike: $7.13 | $50,000,000.00 |
DisclosureSEC source: 0001144204-17-052970 · tv476968_4.xml · derivative · entry 1 Dexxon Holdings Ltd. · CIK 0001636684 · 10% owner Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner Oren Dan · CIK 0001636701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes 3 and 4 Disclosed balance after: 500,000 Underlying: Common shares, no par value · 9,808,386 shares Expires 2021-10-16 F1 · security: Represents series A participating convertible preferred shares (the "Preferred Shares") purchased by Roivant Sciences Ltd. ("Roivant") for $100.00 per Preferred Share (the "Purchase Price"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends. F2 · derivative.exercise_price: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · shares: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · price: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · derivative.exercise_date: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · derivative.expiration_date: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F2 · derivative.underlying_shares: Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the "Preferred Shares Articles Amendment"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the "Common Shares"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares. F3 · ownership.direct: Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the Preferred Shares held by Roivant. Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Preferred Shares. F4 · ownership.direct: Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Preferred Shares owned directly by Roivant. The Reporting Persons do not directly own any Preferred Shares. The Reporting Persons disclaim beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.